Soybean isoflavones attenuate the expression of genes related to endometrial cancer risk

Soybean isoflavones attenuate the expression of genes related to endometrial cancer risk

Autor Ferraz Carbonel, A. A. Autor UNIFESP Google Scholar
Longoni Calio, M. Autor UNIFESP Google Scholar
Aparecida Santos, M. Autor UNIFESP Google Scholar
Antonio Bertoncini, C. R. Autor UNIFESP Google Scholar
Silva Sasso, G. da Autor UNIFESP Google Scholar
Santos Simoes, R. Google Scholar
Jesus Simoes, M. Autor UNIFESP Google Scholar
Soares, J. M. Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Resumo Objective We evaluated whether genistein or estrogen treatment has the same effect when administered immediately or late to rats induced with menopause using ovariectomy.Methods Sixty adult female rats were divided into six treatment groups: GI = vehicle immediately after ovariectomy; GII = vehicle 30 days after ovariectomy; GIII = genistein immediately after ovariectomy; GIV = genistein 30 days after ovariectomy; GV = estrogen immediately after ovariectomy; and GVI = estrogen 30 days after ovariectomy. All animals were treated for 30 consecutive days. At the end of the treatment, part of the uteri was removed for subsequent histological studies and another part was used to evaluate estrogen receptors 1 and 2, cell proliferation (cyclin A1 and A2, cyclin D1, cyclin-dependent kinase inhibitors 1, 1B and 2, antigen identified by the monoclonal antibody Ki67) and angiogenesis (vascular endothelial growth factor, VEGF-A) gene expression.Results Late treatment after castration in rats resulted in more developed endometrium, enhanced cell proliferation and estrogen-signalling pathways, particularly the cyclin-related genes Ki67 and VEGF-A, compared to early treatment. Interestingly, these same effects were less intense with genistein compared to those induced by estrogen, especially when genistein was administered late.Conclusion Our data show that isoflavone renders a lower risk of cancer when compared to estrogen in treatments.
Assunto 17 beta-ESTRADIOL
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Data 2015-06-01
Publicado em Climacteric. London: Informa Healthcare, v. 18, n. 3, p. 389-398, 2015.
ISSN 1369-7137 (Sherpa/Romeo, fator de impacto)
Editor Informa Healthcare
Extensão 389-398
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000354403800014

Mostrar registro completo

Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)